Basal cell carcinoma (BCC) is the most common malignancy of the skin and arises from basal keratinocytes in the epidermis or from follicular structures. It is characterized by indolent local growth with a strong propensity to invade surrounding tissue while metastasizing rarely. In clinical practice, BCC represents a paradigm of “locally aggressive” cancer biology: most cases are curable when detected early, yet delayed treatment can lead to destructive invasion of cartilage, muscle, or bone.
Biologically, BCC is driven by aberrant signaling in developmental pathways, most notably the Hedgehog pathway. Activation of Hedgehog signaling—classically through mutations such as PTCH1 or SMO—promotes proliferation and survival of tumor cells and supports tumor architecture that mirrors basal cell differentiation. Histologically, BCC may appear in multiple patterns, including nodular, superficial, infiltrative, micronodular, and morpheaform (sclerosing) variants. These subtypes differ in growth pattern and depth of invasion, which directly influences management decisions. Perineural invasion may occur, especially in high-risk anatomical sites, and can correlate with more complex surgical planning.
Epidemiologically, the most important risk factor is cumulative ultraviolet (UV) radiation exposure, particularly chronic sun exposure common in outdoor occupations. Intermittent intense sunburns also increase risk, especially in individuals with fair skin, light eye color, and inability to tan effectively. BCC is associated with increasing age, male sex, and geographic latitude linked to UV intensity. Additional risk factors include prior radiation therapy, arsenic exposure, immunosuppression (e.g., transplant recipients), and genetic syndromes such as basal cell nevus syndrome (Gorlin syndrome), where multiple BCCs develop at a young age due to germline pathway defects.
Clinically, BCC often presents as a pearly or translucent papule with telangiectatic vessels, a rolled border, or ulceration (sometimes described as a “rodent ulcer”). Superficial BCC may manifest as a scaly erythematous patch resembling eczema or psoriasis. Infiltrative and morpheaform BCC can appear as ill-defined, scar-like lesions with subtle surface changes, increasing the risk of underestimation of true tumor extent. Because BCC rarely spreads distantly, staging typically focuses on local invasion and high-risk features rather than distant metastasis.
Diagnosis begins with careful dermatologic examination and dermoscopy, followed by biopsy confirmation. The choice of biopsy (shave, punch, or excisional) depends on lesion size, site, and suspected subtype. Histopathology confirms diagnosis and variant, evaluates margins when appropriate, and may assess perineural involvement. Imaging is generally reserved for lesions with suspected deep invasion, recurrent disease, or neurologic symptoms suggestive of perineural spread.
Treatment depends on tumor subtype, size, location, histologic risk, and patient factors. Standard options include surgical excision and Mohs micrographic surgery. Mohs surgery offers maximal margin control by examining tissue layers in real time and is especially valuable for tumors in cosmetically or functionally critical areas (e.g., face, ears, eyelids, nose) or for recurrent/infiltrative lesions. For low-risk superficial disease, topical therapies such as imiquimod or chemotherapeutic approaches may be used, though cure rates and indications vary. Destructive modalities (e.g., cryotherapy or curettage with electrodessication) can be effective for select superficial or small lesions. Radiation therapy is another option for patients who are not surgical candidates or when surgery would cause unacceptable morbidity.
Systemic therapy is considered for advanced BCC when surgery or radiation is not feasible. Hedgehog pathway inhibitors (including agents targeting SMO) can shrink tumors and reduce local disease burden, particularly in locally advanced cases or in patients with extensive unresectable tumors. Supportive care includes wound management, scar counseling, and long-term skin surveillance.
Prognosis for most patients is excellent because BCC seldom metastasizes; however, risk of recurrence and progression is linked to histologic subtype, anatomic location, tumor size, incomplete initial treatment, and immunosuppression. Regular dermatologic follow-up is essential due to the high likelihood of developing additional primary skin cancers after a BCC diagnosis.
Preventive strategies are central: consistent sun protection (broad-spectrum sunscreen, protective clothing, and avoidance of peak UV hours), behavioral modifications to reduce burn risk, and prompt evaluation of suspicious lesions. Patient education should emphasize that early recognition of subtle nonhealing bumps, scaly patches, or pearly lesions improves outcomes by enabling less invasive and more margin-sparing treatment.
Source: [@TesLatina]
Nancy_I_O_S 🪐: Basal Cell Carcinoma (BCC) is the most common type of skin cancer. It develops in the basal cells, which are found in the deepest layer of the outer skin (epidermis). Although it rarely spreads to other parts of the body, it can grow deeper and damage surrounding skin, tissue,. #breaking
— @TesLatina May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
